Rubusoside
CAS No. 64849-39-4
Rubusoside( UNII-TCV5K3M3GX )
Catalog No. M18952 CAS No. 64849-39-4
Rubusoside is a solubilizing agent with antiangiogenic and antiallergic properties.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 71 | In Stock |
|
| 5MG | 49 | In Stock |
|
| 10MG | 81 | In Stock |
|
| 25MG | 136 | In Stock |
|
| 50MG | 202 | In Stock |
|
| 100MG | 276 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 684 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRubusoside
-
NoteResearch use only, not for human use.
-
Brief DescriptionRubusoside is a solubilizing agent with antiangiogenic and antiallergic properties.
-
DescriptionRubusoside is a natural sweetener.
-
In Vitro——
-
In Vivo——
-
SynonymsUNII-TCV5K3M3GX
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number64849-39-4
-
Formula Weight642.73
-
Molecular FormulaC32H50O13
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 32 mg/mL; 49.79 mM
-
SMILESCC12CCCC(C1CCC34C2CCC(C3)(C(=C)C4)OC5C(C(C(C(O5)CO)O)O)O)(C)C(=O)OC6C(C(C(C(O6)CO)O)O)O
-
Chemical NameKaur-16-en-18-oic acid, 13-(beta-D-glucopyranosyloxy)-, beta-D-glucopyranosyl ester, (4alpha)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Cimifugin beta-D-glu...
Prim-O-glucosylcimifugin can inhibit the proliferation of SMC(smooth muscle cell) stimulated by TNF-alpha, increase the proportion of G0/G1 phase.
-
8-Bromoguanosine
8-Bromoguanosine is a brominated derivative of guanosine. It is activate lymphocytes through an intracellular mechanism to exert immunostimulatory effects.
-
Lasmiditan
Lasmiditan, also known as COL-144 and LY573144, is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (K1=2.21 μM) without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study.
Cart
sales@molnova.com